Clinical trials: Behaviour Change
Periodontal Diseases, Chronic Periodontitis
Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
The purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status…
- Conditions
- Periodontal Diseases, Chronic Periodontitis, Periodontal Pocket, Tooth Mobility
- Trial name
- NCT03364751
- Testing
- IQOS, Cigarette
- Where
- 26 sites in Japan
- Volunteers
- 179 people
- Sponsor
- Philip Morris Products S.A.
Smoking
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK profiles from a single use of a…
- Trial name
- NCT01967732
- Testing
- THS 2.2, CC, NNS
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking
Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
The main goal of the study is to evaluate if the ad libitum use of the THS 2.2 Menthol (mTHS 2.2) for 5 days in confinement and after 85 days of product use in an ambulatory setting, by Japanese adult healthy smokers results in a…
- Trial name
- NCT01970995
- Testing
- THS 2.2 Menthol (mTHS 2.2), Smoking Abstinence (SA), Menthol Conventional Cigarette (mCC)
- Where
- Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Obesity
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
- Trial name
- NCT00603902
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 4,008 people
- Sponsor
- Eisai Inc.
Obesity
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of…
- Trial name
- NCT00395135
- Testing
- Lorcaserin 10 mg BID
- Where
- United States
- Volunteers
- 3,182 people
- Sponsor
- Eisai Inc.
Tobacco Use
Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products
The purpose of the study is to evaluate changes in biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs) in adult smokers who completely switch to Ploom heated tobacco products (HTPs) compared to…
- Trial name
- NCT06179290
- Testing
- Ploom HTP Menthol HTS; MX3 (681), Ploom HTP Tobacco HTS; R8 (120), Smoking Abstinence (menthol)
- Where
- 8 sites in United States
- Volunteers
- 921 people
- Sponsor
- Altria Client Services LLC
Smoking
Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.
The overall goal of the study is to demonstrate the reduction of biomarkers of exposure (BoExp) to selected harmful and potentially harmful constituents (HPHCs) in adult smokers switching for 5 days from conventional cigarette…
- Trial name
- NCT02503254
- Testing
- CHTP 1.0, Conventional Cigarette (CC)
- Where
- Poland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Tobacco Use
A Study to Evaluate Changes in Smokers Using An Oral Tobacco-Derived Nicotine Product
The purpose of this study was to estimate changes in biomarkers of exposure (BOE) in adult cigarette smokers using an oral tobacco-derived nicotine (OTDN) product relative to adult smokers who continue smoking exclusively.
- Trial name
- NCT04079933
- Testing
- Oral tobacco-derived nicotine product (OTDN)
- Where
- 3 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Altria Client Services LLC
Smoking
Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.
The overall goal of the study is to evaluate if the ad libitum use of the Tobacco Heating System 2.2 (THS 2.2) for 5 days by adult healthy smokers results in a reduction in the levels of biomarkers of exposure (BoExp) for…
- Trial name
- NCT01959932
- Testing
- Tobacco Heating System (THS 2.2), Smoking abstinence (SA), Conventional cigarette (CC)
- Where
- Poland
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking
Nicotine Pharmacokinetic Profile of the CHTP 1.1 M
The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile of nicotine (rate and amount of nicotine absorbed) after single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M), a…
- Trial name
- NCT02466412
- Testing
- CHTP 1.1 M, mCC
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Tobacco Use
Biomarkers of Exposure and Biomarkers of Potential Harm in Adult Smokers Who Completely Switch to E-vapor Products
The purpose of this study was to estimate changes in biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) in adult cigarette smokers (AS) who switched to using an e-vapor product (EVP) relative to adult smokers…
- Trial name
- NCT04800211
- Testing
- Experimental: Test Product 1, Experimental: Test Product 2
- Where
- 10 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Altria Client Services LLC
Cigarette Smoking
A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation
The purpose of this study was to understand the biological and functional changes after one year of smoking cessation and to collect data on a broad range of biomarkers of exposure (BoExp) and biomarkers of effect (BoE).
- Trial name
- RIBESC (NCT02432729)
- Where
- 5 sites in United States, Germany and 3 more
- Volunteers
- 1,184 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Pulmonary Disease, Chronic Obstructive
Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with…
- Trial name
- NCT04795323
- Testing
- TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Smoking
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
The overall goal of the study is to evaluate the pharmacokinetic (PK) profile (rate and the amount of nicotine absorbed) following a single use of the THS 2.2, a candidate Modified Risk Tobacco Product, compared to the PK…
- Trial name
- NCT01959607
- Testing
- THS 2.2, CC, NRT Gum
- Where
- Japan
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).
The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product…
- Trial name
- NCT01967706
- Testing
- mTHS, mCC, NRT
- Where
- Japan
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking
Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting
Evaluate if the ad libitum use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product, for 5 days in confinement, and after 86 days in an ambulatory setting, by apparently adult healthy smokers results in a…
- Trial name
- NCT01989156
- Testing
- THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA)
- Where
- 2 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Schizophrenia
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
The purpose of this study is to evaluate improvement and efficacy of paliperidone extended-release for subjective well-being and drug attitudes of participants, when switching from oral antipsychotics in participants with…
- Trial name
- Power (NCT00784238)
- Testing
- Paliperidone
- Where
- 11 sites in South Korea
- Volunteers
- 289 people
- Sponsor
- Janssen Korea, Ltd., Korea
Tobacco Use
A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.
The purpose of this study is to evaluate changes in exposure to selected harmful and potentially harmful constituents (HPHC) by measuring biomarkers in adult smokers who partially or completely switch from smoking cigarettes to…
- Trial name
- NCT03692078
- Testing
- OTDN product 1, OTDN product 2, Tobacco Cessation
- Where
- 2 sites in United States
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Altria Client Services LLC
Smoking, Tobacco Product
Japanese Post-Market Cohort Study
The objectives and endpoints of this study were analyzed in the study population of adults eligible to purchase tobacco products.
- Trial name
- NCT03020667
- Where
- Japan
- Volunteers
- 1,124 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking
Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting
The overall goal of the study is to evaluate if the ad libitum use of the Tobacco Heating System 2.2 (THS 2.2) for 5 consecutive days by adult Japanese healthy smokers affects the levels of biomarkers of exposure for selected…
- Trial name
- NCT01970982
- Testing
- Tobacco Heating System (THS 2.2), Smoking abstinence (SA), Conventional cigarette (CC)
- Where
- Japan
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.